new version available

Newsletter Sign Up

Please enter your email to receive FREE venture capital and private equity special offers, news, and information!

Your Name: 

Your Email:  

bookmark us

06/11/2007

BioRelix Announces $25.75 Million Series A Financing

 

BioRelix, Inc., a biopharmaceutical company focused on the development of novel anti-infective agents, announced recently the completion of a $25.75 million Series A financing. The financing was led by CHL Medical Partners with participation by new investors New Leaf Venture Partners and Aisling Capital and existing investors Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities. BioRelix expects to use the funds to build a portfolio of anti-infective product candidates based on novel patented bacterial RNA targets, termed RiboSwitches™, which were identified by the laboratory of BioRelix’ co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University.

“We are extremely pleased to have a prestigious group of investors who support the company’s strategy and approach to building a pipeline of anti-bacterial products,” stated Ronald W. Lennox, D. Phil., a partner with CHL Medical Partners and interim CEO. “We anticipate that the Series A financing will allow us to file an IND with at least one RiboSwitch class and advance other compounds targeting different RiboSwitch classes through late stage pre-clinical development. In the near term, we expect to have a CEO in place by early fall of this year.”

In connection with the Series A financing, Philippe Chambon, M.D., Ph.D., Managing Director of NLV Partners, Dov A. Goldstein, M.D., Principal of Aisling Capital, and Campbell Murray, M.D., Managing Director of Novartis Venture Fund, have been added to the BioRelix Board of Directors. Current directors of the company also include Ronald Lennox, D. Phil, Professor A. Donny Strosberg, Dr. Sci., of the Scripps Research Institute and William Wiesler, Ph.D., of Yale University.

Dr. Breaker commented, “BioRelix’ proprietary technology platform addresses the widespread and growing prevalence of resistant bacterial strains that are presenting in both the hospital and community settings. RiboSwitches constitute the first new major class of targets for anti-infective drug discovery in decades and in fact seem to underlie the activity of several compounds with known antibacterial activity. Our recent research has also demonstrated that RiboSwitches may have broad-spectrum activity against Gram-positive and Gram-negative bacteria. We are continuing to explore the mechanism of action of this class of targets, including the potential to reduce toxicity, as well as possible applications in anti-fungal therapy.”

For more information, please visit www.biorelix.com